Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: mark alan rosenberg who wrote (77)	5/9/1998 6:52:00 PM
From: David Wise	Read Replies (1) \| Respond to of 395

I called company and got investor's package last year. They've been working a long time on anti-angiogenesis drug. Their's is synthetic type, so will be easier to produce in large quantities, unlike ENMD's. Suggest you check a news article for their phone number and call. Note that Pfiser (Viagra) is some way involved with company. Also, it is VERY encouraging that National Cancer Institute was interested enough to give a $750,000 grant last month. With market cap in the 30's, this appears to be the best bargain out there. And no hype from the company - so when there's an announcement, Repligen could act like ENMD. Here's hoping!